Cost-utility of tDCS in depression treatment

ABSTRACT: Depression is one of the most common psychiatric disorders causing considerable economic burden. However, the current treatment as usual, pharmacotherapy and psychotherapy, provides unsatisfactory treatment outcome for majority of the patients and in most cases fails to prevent treatment r...

Descripción completa

Detalles Bibliográficos
Autor principal: Sauvaget, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417902/
http://dx.doi.org/10.1192/j.eurpsy.2023.166
_version_ 1785088149729312768
author Sauvaget, A.
author_facet Sauvaget, A.
author_sort Sauvaget, A.
collection PubMed
description ABSTRACT: Depression is one of the most common psychiatric disorders causing considerable economic burden. However, the current treatment as usual, pharmacotherapy and psychotherapy, provides unsatisfactory treatment outcome for majority of the patients and in most cases fails to prevent treatment resistance and chronicity. tDCS, has emerged as a new neuromodulation treatment and has shown efficacy in depressed patients. To provide important insight to the payers, the cost-utility of tDCS in comparison to treatment as usual, should be clarified. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10417902
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-104179022023-08-12 Cost-utility of tDCS in depression treatment Sauvaget, A. Eur Psychiatry Abstract ABSTRACT: Depression is one of the most common psychiatric disorders causing considerable economic burden. However, the current treatment as usual, pharmacotherapy and psychotherapy, provides unsatisfactory treatment outcome for majority of the patients and in most cases fails to prevent treatment resistance and chronicity. tDCS, has emerged as a new neuromodulation treatment and has shown efficacy in depressed patients. To provide important insight to the payers, the cost-utility of tDCS in comparison to treatment as usual, should be clarified. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10417902/ http://dx.doi.org/10.1192/j.eurpsy.2023.166 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Sauvaget, A.
Cost-utility of tDCS in depression treatment
title Cost-utility of tDCS in depression treatment
title_full Cost-utility of tDCS in depression treatment
title_fullStr Cost-utility of tDCS in depression treatment
title_full_unstemmed Cost-utility of tDCS in depression treatment
title_short Cost-utility of tDCS in depression treatment
title_sort cost-utility of tdcs in depression treatment
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417902/
http://dx.doi.org/10.1192/j.eurpsy.2023.166
work_keys_str_mv AT sauvageta costutilityoftdcsindepressiontreatment

Ejemplares similares